ReviewFrontiers in immunology2021
Depression and Obesity in Patients With Psoriasis and Psoriatic Arthritis: Is IL-17-Mediated Immune Dysregulation the Connecting Link?
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 48 citations in OpenAlex.
- DYRK kinases phosphorylate IL-17RA at S801.Serican journal of medicine · 2026Article
- Psychometric Evaluation of Patients with Psoriasis and their Association with Patients' Psychological Characteristics.Mediterranean journal of rheumatology · 2026Article
- Altered subgenual anterior cingulate cortex connectivity in psoriasis patients with depression: a resting-state fMRI case-control study.Annals of general psychiatry · 2026Article
- Clinical value of IL-17-targeted intervention in tissue injury repair: from bidirectional mechanisms to therapeutic strategies.Frontiers in immunology · 2026Review
- Mechanisms and active components ofFrontiers in immunology · 2026Article
- Disrupted betaine metabolism drives Th17 cell differentiation, mediating methamphetamine-induced depressive behaviors in male mice.Journal of neuroinflammation · 2025Article
- Prevalence and factors associated with fatigue in patients with psoriatic arthritis: a systematic review and meta-analysis.BMC rheumatology · 2025Article
- Article
- Safety assessment of apremilast: real-world adverse event analysis from the FAERS database.Archives of dermatological research · 2025Article
- The complex interplay between psoriasis and depression: from molecular mechanisms to holistic treatment approaches.Frontiers in immunology · 2025Review
- A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab.Frontiers in pharmacology · 2025Article
- Psychological distress in young adults with well-controlled psoriasis.Frontiers in psychiatry · 2025Article
- The Role of Metabolic Syndrome in Psoriasis Treatment Response: A One-Year Comparative Analysis of PASI Progression.Diagnostics (Basel, Switzerland) · 2024Article
- Altered serum interleukin-17A and interleukin-23A levels may be associated with the pathophysiology and development of generalized anxiety disorder.Scientific reports · 2024Article
- Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).Dermatology practical & conceptual · 2024Article
- Article
- IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.Frontiers in immunology · 2024Review
- Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy.Therapeutic advances in musculoskeletal disease · 2024Review
- The bidirectional causal association between psoriasis and psychological illnesses: a 2-sample Mendelian randomization study.Archives of dermatological research · 2023Article
- Downregulated NPAS4 in multiple brain regions is associated with major depressive disorder.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with psoriasis are frequently obese and experience anxiety or suffer from depressive disorders. The immunopathogenesis of psoriasis and indeed psoriatic arthritis is largely based on the pivotal role of IL-17/IL-23 axis, to an extent that currently monoclonal antibodies selectively inhibiting IL-17 or IL-23 are routinely used for the treatment of psoriatic diseases. Emerging data, demonstrating a decisive role for IL-17 and IL-17 producing cell subsets, such as Th17 in the induction and progression of obesity and depression has led authors to suggest that psoriatic disease, obesity and anxiety/depression may indeed be interconnected manifestation of a state of immunedysregulation, the linked being IL-17 and its related cells. We discuss this hypothetical link in depth taking into account the beneficial effects anti-IL17 and anti-IL-17 receptor inhibitors in treating psoriatic disease and the on-going debate as to whether these biologics may exert a direct or indirect effect in ameliorating concomitant obesity and depressive disorders, which are frequently noted in the same patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.